List of Excipients in Branded Drug VELSIPITY

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Pfizer Laboratories Div Pfizer Inc	VELSIPITY	etrasimod	0069-0274	CELLULOSE, MICROCRYSTALLINE	2036-06-21
Pfizer Laboratories Div Pfizer Inc	VELSIPITY	etrasimod	0069-0274	FD&C BLUE NO. 1 ALUMINUM LAKE	2036-06-21
Pfizer Laboratories Div Pfizer Inc	VELSIPITY	etrasimod	0069-0274	FD&C BLUE NO. 2 ALUMINUM LAKE	2036-06-21

VELSIPITY Excipient Strategy and Commercial Opportunities

Last updated: August 30, 2026

VELSIPITY, Pfizer’s oral etrasimod product for moderately to severely active ulcerative colitis, uses a conventional immediate-release film-coated tablet. The commercial opportunity for excipient suppliers, generic manufacturers and lifecycle developers is concentrated in four areas: low-dose content uniformity, robust film coating, differentiated oral dosage forms and global supply-chain optimization. The reference formulation is relatively simple, which lowers manufacturing barriers but also makes generic substitution and formulation competition more feasible.

What is VELSIPITY and how is it formulated?

VELSIPITY contains etrasimod arginine, equivalent to 2 mg of etrasimod, in a once-daily oral tablet. The U.S. Food and Drug Administration approved VELSIPITY on Oct. 26, 2023, for adults with moderately to severely active ulcerative colitis who have had an inadequate response or intolerance to one or more approved therapies.[1]

The U.S. prescribing information describes the product as a 2 mg film-coated tablet. The disclosed inactive ingredients include:

Formulation element	Reported function
Lactose monohydrate	Diluent and tablet-volume adjustment
Microcrystalline cellulose	Filler and dry-binder support
Croscarmellose sodium	Superdisintegrant
Magnesium stearate	Lubricant
Film-coating materials	Color, protection, swallowability and product identification

The product is an immediate-release dosage form rather than an extended-release tablet, enteric-coated product or depot formulation. That distinction is commercially important. A generic manufacturer is likely to pursue a relatively conventional immediate-release formulation, while differentiated products would need to create a clinical, adherence, pediatric or manufacturing advantage.

Etrasimod is a sphingosine-1-phosphate receptor modulator. The active ingredient has pharmacologic and safety characteristics that make formulation control important. The label includes warnings involving bradyarrhythmia, atrioventricular conduction delay, macular edema, liver injury, hypertension, pulmonary effects, infections and fetal risk.[1] Excipient selection does not remove those risks, but changes in dissolution, absorption or patient tolerability can affect clinical comparability.

What excipient strategy best fits VELSIPITY?

The most defensible strategy is a simple, immediate-release formulation with tight control over API dispersion, tablet disintegration and coating uniformity.

Low-dose content uniformity

A 2 mg dose creates a relatively high excipient-to-API ratio. Manufacturing risk therefore centers on:

• API distribution throughout the blend;
• segregation during transfer and compression;
• assay uniformity at commercial scale;
• sensitivity to particle-size variation;
• control of the etrasimod arginine salt during granulation or blending.

Direct compression can reduce process steps, but it may be less forgiving if the API has poor flow or limited bulk density. A dry-granulation process may improve flow and segregation resistance, although it adds equipment, compaction and granule-size controls.

Potential excipient solutions include co-processed microcrystalline cellulose, silicified microcrystalline cellulose, spray-dried lactose and low-level glidants. These materials can improve blend uniformity and tablet robustness without changing the immediate-release profile materially.

Disintegration and dissolution

Croscarmellose sodium is a logical disintegrant for the reference-type formulation. Generic developers may evaluate crospovidone, sodium starch glycolate or co-processed disintegrant systems as alternatives.

The commercial objective is not simply rapid disintegration. It is reproducible dissolution across:

• API particle-size lots;
• tablet hardness ranges;
• compression-force changes;
• humidity exposure;
• scale-up batches;
• global excipient grades.

Magnesium stearate concentration and blending time require particular control. Excessive lubrication can reduce tablet wetting and slow dissolution. This risk is relevant for low-dose immediate-release products because a small change in release behavior can create a disproportionate effect on bioequivalence performance.

Salt and solid-state control

The product uses etrasimod arginine rather than an unspecified free form of etrasimod. The salt form may influence hygroscopicity, crystallinity, dissolution and blend behavior. Excipient compatibility studies should therefore evaluate:

• moisture uptake;
• polymorphic or solid-state changes;
• chemical degradation;
• interaction with reducing sugars;
• lubricant sensitivity;
• stability under accelerated conditions.

Lactose is commercially attractive because it is inexpensive, widely available and familiar to regulators. It also creates a potential development issue if the API or salt shows sensitivity to moisture or solid-state change. Alternative fillers such as mannitol, dibasic calcium phosphate or selected grades of microcrystalline cellulose could support differentiated formulations, but each substitution would require dissolution, stability and bioequivalence assessment.

What formulation patents protect VELSIPITY?

Public product information confirms that VELSIPITY is protected through a combination of active-ingredient, use, formulation and regulatory exclusivity rights. The exact enforceable scope depends on the current FDA Orange Book listing, patent-family prosecution history and any terminal disclaimers.

The principal commercial categories are:

Protection category	Relevance to VELSIPITY
Etrasimod composition-of-matter rights	Protect the active chemical entity or salt
Pharmaceutical composition claims	Can cover etrasimod with carriers or excipient classes
Method-of-use claims	May cover treatment of ulcerative colitis or dosing regimens
Solid-form or salt claims	May protect etrasimod arginine or specific crystalline forms
Manufacturing claims	May cover preparation of the active ingredient or drug product
Regulatory exclusivity	Can delay certain generic approvals even without patent litigation

An excipient substitution does not automatically avoid a formulation patent. A patent may claim a broad pharmaceutical composition, a specific salt, a dissolution profile, a defined dosage range or a manufacturing step. A generic company must assess claim scope, prosecution history and infringement risk rather than rely on a different filler or lubricant.

What is the Orange Book status of VELSIPITY?

VELSIPITY is an FDA-approved small-molecule drug and is eligible for Orange Book listing of patents that meet FDA requirements. The approval date creates a five-year new chemical entity exclusivity period, subject to FDA regulatory rules and any qualifying pediatric extension. Based on the Oct. 26, 2023 approval date, the baseline NCE exclusivity period runs to Oct. 26, 2028.[1,2]

Orange Book patent listings and expiration dates can change through listing updates, patent-term adjustment, patent-term extension, reissued patents and litigation outcomes. The relevant question for a generic applicant is not the number of listed patents alone. It is whether the patents create a valid approval barrier, a Paragraph IV litigation risk or a launch-timing constraint.

When does VELSIPITY lose exclusivity?

VELSIPITY’s first major statutory barrier is the five-year NCE exclusivity period ending in October 2028, absent a qualifying pediatric extension or other regulatory change. Patent protection may extend beyond that date. Generic companies can submit ANDAs before NCE exclusivity expires, but approval timing depends on the relevant patent certifications and listed patent dates.

A generic launch could occur through several paths:

1. A first-filer Paragraph IV applicant obtains 180-day exclusivity.
2. An applicant waits for listed patents to expire.
3. An applicant reaches a settlement permitting an agreed launch date.
4. An applicant challenges patents and launches at risk after litigation developments.
5. A non-infringing formulation avoids selected composition or formulation claims.

What generic entry risks exist for VELSIPITY?

The generic risk profile is moderate rather than structurally high or low.

Factors that support generic entry

VELSIPITY has characteristics that generally favor formulation competition:

• It is an oral immediate-release tablet.
• It does not require a complex delivery device.
• It does not use a biologic manufacturing platform.
• The disclosed excipient system is conventional.
• The dose is fixed and once daily.
• The product does not depend on an extended-release mechanism.

These features can reduce development cost and shorten scale-up compared with biologics, inhaled products, long-acting injectables or complex modified-release systems.

Factors that increase development difficulty

The low 2 mg strength creates technical challenges. A generic applicant must demonstrate reliable content uniformity and bioequivalence while controlling the etrasimod arginine salt. Small changes in disintegration, dissolution or API distribution could affect pharmacokinetic comparability.

The drug’s safety monitoring requirements also increase commercial complexity. Generic labeling must remain consistent with the reference product’s safety information, and any proposed formulation change must not create a clinically meaningful exposure difference.

Are there public Paragraph IV challenges?

A Paragraph IV challenge would require an ANDA applicant to certify that an Orange Book patent is invalid, unenforceable or not infringed. Publicly visible regulatory and court information does not establish a material, widely reported Paragraph IV dispute that has already changed VELSIPITY’s market timetable. The principal near-term barrier remains regulatory exclusivity through October 2028, followed by the enforceability of Pfizer- and Arena-related patent rights.

A Paragraph IV filing could still emerge before or during that period. The most likely targets would be narrow formulation, salt, method-of-use or manufacturing claims rather than the basic immediate-release tablet concept.

What excipient commercial opportunities exist around VELSIPITY?

Opportunity 1: Generic-grade excipient substitution

Excipient suppliers can target generic development programs with materials that provide:

• improved low-dose blend uniformity;
• lower lubricant sensitivity;
• faster and more consistent disintegration;
• reduced moisture uptake;
• global regulatory availability;
• robust performance at high-speed compression.

The strongest commercial proposition is a platform excipient supported by comparative dissolution, scale-up and stability data rather than a simple alternative to lactose or microcrystalline cellulose.

Opportunity 2: Lactose-free and patient-segment formulations

A lactose-free VELSIPITY-equivalent formulation could support patients with lactose intolerance, excipient preferences or regional formulation requirements. Mannitol, microcrystalline cellulose and selected calcium phosphate systems are potential substitutes, although taste, hardness, friability and dissolution must remain controlled.

The commercial value is likely to be incremental rather than transformational because the reference product is swallowed whole and the label does not identify a broad lactose-related positioning strategy.

Opportunity 3: Pediatric and adherence formats

Etrasimod is currently positioned for adults. Pediatric ulcerative colitis creates a potential lifecycle opportunity for:

• mini-tablets;
• dispersible tablets;
• sprinkle formulations;
• oral granules;
• lower-strength tablets;
• caregiver-friendly packaging.

Any pediatric presentation would need to address dose flexibility, palatability, stability after dispersion and age-appropriate administration. A new dosage form may require a supplemental application, a 505(b)(2) pathway or another regulatory strategy depending on the formulation and requested labeling.

Opportunity 4: Global supply-chain resilience

A formulation that uses common, multi-source excipients can reduce manufacturing risk across the United States, Europe and other regulated markets. Suppliers with compendial grades recognized under USP-NF, Ph. Eur. and JP standards can improve procurement flexibility.

The most valuable supply-chain attributes are:

• multiple qualified manufacturing sites;
• consistent particle-size distribution;
• low variability in moisture and bulk density;
• reliable regulatory documentation;
• validated change-control processes;
• availability at commercial scale.

Opportunity 5: Manufacturing process improvement

Co-processed excipients may allow direct compression with better flow and lower segregation risk. A developer could also use engineered lactose or cellulose grades to reduce blend-time sensitivity.

This opportunity is strongest where a supplier can show measurable improvement in:

• weight variation;
• assay uniformity;
• tablet tensile strength;
• friability;
• dissolution after accelerated storage;
• compression-speed operating range.

How does VELSIPITY compare with competing ulcerative-colitis drugs?

VELSIPITY competes with oral small molecules and biologic therapies, including ozanimod, tofacitinib, upadacitinib, anti-TNF products, vedolizumab and ustekinumab. Its excipient opportunity differs from biologic competitors because VELSIPITY is a conventional tablet rather than an injectable or infusion product.

Product	Active ingredient	Dosage platform	Excipient opportunity
VELSIPITY	Etrasimod arginine	Immediate-release tablet	Low-dose uniformity, lactose-free, pediatric and generic formulations
ZEPOSIA	Ozanimod hydrochloride	Capsules	Capsule-fill, multiparticulate and kit packaging
XELJANZ	Tofacitinib citrate	Immediate-release and extended-release tablets	Release control, tablet robustness and generic substitution
RINVOQ	Upadacitinib	Extended-release tablet	Controlled-release technology and coating systems
Biologic therapies	Various antibodies	Injection or infusion	Sterility, buffers, surfactants and container closure

VELSIPITY is more directly exposed to conventional oral generic competition than injectable biologics. Its competitive advantage therefore depends on clinical positioning, physician adoption, payer access, safety perception and patent duration rather than formulation complexity alone.

What licensing deals and commercial partnerships affect VELSIPITY?

VELSIPITY originated from Arena Pharmaceuticals and became part of Pfizer’s portfolio through Pfizer’s acquisition of Arena in 2022. Pfizer is the principal commercial owner and regulatory sponsor for VELSIPITY in major markets.[3]

No separate public excipient-focused licensing transaction has established a distinctive commercial position for a particular excipient supplier. The practical partnership opportunities are more likely to arise through:

• contract development and manufacturing organizations;
• generic formulation collaborations after regulatory barriers weaken;
• regional commercialization agreements;
• pediatric lifecycle-development partners;
• excipient suppliers with formulation-development platforms.

What is the revenue exposure and commercial outlook?

VELSIPITY’s commercial value is tied to the large ulcerative-colitis treatment market and the shift toward oral therapies. Revenue exposure will depend on whether the product is used earlier in treatment, how payers position it against biologics and JAK inhibitors, and whether Pfizer expands the label.

For excipient businesses, the addressable opportunity is smaller than the API or finished-dose opportunity. It is also recurring. A successful excipient platform can supply clinical, registration, validation and commercial batches across multiple manufacturers.

The highest-value targets are likely to be:

1. Pfizer’s own commercial supply chain.
2. Regional manufacturers preparing post-exclusivity products.
3. CDMOs developing oral small-molecule formulations.
4. Pediatric or differentiated dosage-form developers.
5. Suppliers able to support multi-region regulatory filings.

How strong is the VELSIPITY patent estate?

The estate is likely strongest around the active ingredient, salt or solid form, therapeutic use and regulatory exclusivity. It is weaker from a formulation-barrier perspective if the marketed tablet relies mainly on conventional excipients and immediate-release technology.

A practical strength assessment is:

Patent or protection layer	Commercial strength
Core etrasimod composition	Potentially strong, subject to expiration and validity
Etrasimod arginine salt or solid form	Potentially strong if narrowly claimed and technically distinct
Ulcerative-colitis method claims	Variable, depending on claim scope and prior art
Conventional excipient combination	Usually moderate to weak unless narrowly optimized
Immediate-release tablet architecture	Generally easier to design around
FDA NCE exclusivity	Strong until October 2028 under the baseline timeline

Manufacturing patents may create additional barriers if they cover a commercially necessary API route or a specific solid form. They are less decisive when alternative routes or forms are available.

Key Takeaways

• VELSIPITY is a 2 mg immediate-release film-coated tablet containing etrasimod arginine.
• The principal excipient strategy is conventional and centers on content uniformity, disintegration, dissolution and coating control.
• Low-dose manufacturing creates the main technical challenge for generic developers.
• Lactose-free, pediatric, dispersible and mini-tablet formats offer the clearest lifecycle opportunities.
• FDA NCE exclusivity runs to October 2028 based on the Oct. 26, 2023 approval date, before considering any pediatric extension or patent-based barriers.
• Generic entry risk is higher than for biologic ulcerative-colitis therapies because VELSIPITY is a conventional oral small molecule.
• Pfizer’s acquisition of Arena Pharmaceuticals is the main disclosed commercial transaction affecting the product.
• Excipient suppliers with co-processed, low-variability and globally qualified materials have the strongest commercial proposition.

FAQs about VELSIPITY excipients and market opportunities

Can VELSIPITY be reformulated as an orally disintegrating tablet?

Yes, technically, but the developer would need to demonstrate comparable exposure, stability, mechanical performance and acceptable taste. The regulatory pathway would depend on the extent of the change and the proposed labeling.

Is lactose the main formulation vulnerability for VELSIPITY?

Lactose is a potential substitution target, but it is not necessarily the principal technical vulnerability. Blend uniformity, salt stability, lubrication and dissolution may be more important development risks.

Could a generic VELSIPITY use different excipients?

Yes. A generic drug need not duplicate every inactive ingredient, provided it meets applicable pharmaceutical equivalence, bioequivalence, quality and regulatory requirements. Patent claims may still restrict particular compositions or salt forms.

Does VELSIPITY require a biologic biosimilar pathway?

No. Etrasimod is a synthetic small molecule. A competing product would generally pursue an ANDA or, for certain differentiated products, a 505(b)(2) pathway rather than a biosimilar application.

What is the most attractive post-exclusivity VELSIPITY opportunity?

The most practical opportunity is a conventional generic tablet supported by a robust low-dose manufacturing process. A higher-margin opportunity could come from pediatric or adherence-oriented dosage forms, but those products would face greater development and regulatory requirements.

References

1. U.S. Food and Drug Administration. (2023). VELSIPITY (etrasimod) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216830s000lbl.pdf
2. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
3. Pfizer Inc. (2022). Pfizer completes acquisition of Arena Pharmaceuticals. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-completes-acquisition-arena-pharmaceuticals